ArticleResearch square2026
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Surgery: A Pilot Case Series.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Postoperative cognitive impairment is a common complication following coronary artery bypass grafting (CABG) and is thought to arise from perioperative neurovascular injury, systemic inflammation, and neuroaxonal damage. Despite its clinical impact, there are no approved pharmacologic strategies to mitigate postoperative cognitive vulnerability. Angiotensin-(1-7) (Ang-(1-7); PNA1), a Mas receptor agonist, has demonstrated neurovascular and anti-inflammatory effects in preclinical models, but its perioperative cognitive effects in humans have not been described. Case presentation: This case series reports outcomes from an incompletely accrued randomized, double-blind, placebo-controlled pilot study in older adults undergoing elective CABG. Five participants (mean age 64.6 years; 80% male) completed all study procedures; three received Ang-(1-7) (200 μg/kg/day subcutaneously) and two received saline as the placebo. Study drug administration was initiated intraoperatively within two hours of chest opening and continued daily for 21 days. Cognitive performance was assessed at baseline and 21 days postoperatively using standardized neuropsychological measures, including face-name associative memory and executive function tasks. Neuroaxonal injury was evaluated using plasma neurofilament light chain (NfL) measured by ultrasensitive single-molecule array assays. Perioperative glucose regulation, blood pressure, renal function, and adverse events were monitored for safety. Participants receiving Ang-(1-7) demonstrated relative preservation of associative memory and attenuation of postoperative NfL levels compared with placebo-treated participants, with no drug-relted adverse events or clinically significant renal or hemodynamic complications observed. Conclusions: In this small perioperative case series, Ang-(1-7) administration following CABG was feasible and well tolerated and was associated with signals of cognitive preservation and reduced neuroaxonal injury during early postoperative recovery. These findings support further investigation of Ang-(1-7) as a potential perioperative strategy to mitigate postoperative cognitive vulnerability in patients undergoing cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.